These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 2581074)

  • 1. Antiarrhythmic effects of flecainide against canine ventricular arrhythmias induced by two-stage coronary ligation and halothane-epinephrine.
    Dobmeyer D; Muir WW; Schaal SF
    J Cardiovasc Pharmacol; 1985; 7(2):238-44. PubMed ID: 2581074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of SUN-1165, N-(2,6-dimethylphenyl)-8-pyrrolizidine acetamide hydrochloride hemihydrate, a new class I antiarrhythmic drug, on ventricular arrhythmias, intraventricular conduction, and the refractory period in canine myocardial infarction.
    Hashimoto H; Satoh N; Nakashima M
    J Cardiovasc Pharmacol; 1992 Mar; 19(3):417-24. PubMed ID: 1378123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts.
    Coromilas J; Saltman AE; Waldecker B; Dillon SM; Wit AL
    Circulation; 1995 Apr; 91(8):2245-63. PubMed ID: 7697855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of flecainide on ventricular arrhythmias, abnormal automaticity and activation in a canine model of myocardial infarction.
    Hashimoto H; Katoh H; Nakashima M
    J Pharmacobiodyn; 1992 May; 15(5):191-201. PubMed ID: 1527695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of antidepressants, amitriptyline, and maprotiline on intraventricular conduction, effective refractory period, and incidence of ventricular arrhythmias induced by programmed stimulation in dog hearts after myocardial infarction.
    Hashimoto H; Nishimoto M; Ozaki T; Oohara K; Nakashima M
    J Cardiovasc Pharmacol; 1990 Nov; 16(5):693-701. PubMed ID: 1703589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers.
    Ikeda N; Singh BN; Davis LD; Hauswirth O
    J Am Coll Cardiol; 1985 Feb; 5(2 Pt 1):303-10. PubMed ID: 3968315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiarrhythmic effect of oxprenolol on halothane-epinephrine and coronary ligation induced ventricular arrhythmias in beagle dogs.
    Hashimoto K; Tsukada T; Matsuda H; Matsubara I; Imai S
    Jpn J Pharmacol; 1978 Aug; 28(4):535-44. PubMed ID: 32416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide.
    Xue YX; Arita J; Aye NN; Hashimoto K
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Dec; 358(6):649-56. PubMed ID: 9879724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of lethal ischemic ventricular arrhythmias by the class III agent E4031 in a canine model of previous myocardial infarction.
    Lynch JJ; Heaney LA; Wallace AA; Gehret JR; Selnick HG; Stein RB
    J Cardiovasc Pharmacol; 1990 May; 15(5):764-75. PubMed ID: 1692937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of E-4031, a new class III antiarrhythmic drug, on reentrant ventricular arrhythmias: comparison with conventional class I drugs.
    Ogawa S; Mitamura H; Katoh H
    Cardiovasc Drugs Ther; 1993 Aug; 7 Suppl 3():621-6. PubMed ID: 8251432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical usefulness of flecainide acetate in the treatment of paroxysmal supraventricular arrhythmias.
    Camm AJ; Hellestrand KJ; Nathan AW; Bexton RS
    Drugs; 1985; 29 Suppl 4():7-13. PubMed ID: 4006783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiological effects of flecainide in a canine 7 day old myocardial infarction model.
    Sakai T; Ogawa S; Hosokawa M; Miyazaki T; Sakurai K; Nakamura Y
    Cardiovasc Res; 1989 Mar; 23(3):177-83. PubMed ID: 2512008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiarrhythmic effects of the class 1c antiarrhythmic drug, flecainide, on canine ventricular arrhythmia models.
    Akiyama K; Hashimoto K
    Jpn Heart J; 1989 Jul; 30(4):487-95. PubMed ID: 2509760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of an anesthetized dog model of transient cardiac ischemia and rapid pacing: a pilot study for preclinical assessment of the potential for proarrhythmic risk of novel drug candidates.
    Damiano BP; van der Linde HJ; Van Deuren B; Somers Y; Lubomirski M; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2015; 72():72-84. PubMed ID: 25450838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic effects of bupuranolol against canine ventricular arrhythmias induced by halothane-adrenaline or two-stage coronary ligation.
    Hashimoto K; Tsukada T; Matsuda H; Nakagawa Y; Imai S
    J Cardiovasc Pharmacol; 1979; 1(2):205-17. PubMed ID: 94390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiological and haemodynamic effects of vernakalant and flecainide in dyssynchronous canine hearts.
    van Middendorp LB; Strik M; Houthuizen P; Kuiper M; Maessen JG; Auricchio A; Prinzen FW
    Europace; 2014 Aug; 16(8):1249-56. PubMed ID: 24481779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of antiarrhythmic agents in preventing halothane-epinephrine arrhythmias in rats.
    Takada K; Sumikawa K; Kamibayashi T; Hayashi Y; Yamatodani A; Kawabata K; Yoshiya I
    Anesthesiology; 1993 Sep; 79(3):563-70. PubMed ID: 8363083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiological effects of a new antiarrhythmic agent, flecainide, on the intact canine heart.
    Hodess AB; Follansbee WP; Spear JF; Moore EN
    J Cardiovasc Pharmacol; 1979; 1(4):427-39. PubMed ID: 94620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic effects of a novel class III drug, KCB-328, on canine ventricular arrhythmia models.
    Xue Y; Tanabe S; Nabuchi Y; Hashimoto K
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):239-47. PubMed ID: 9700986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.